Canada Health Alliance

Blockbuster Weight-Loss Drug Linked to Serious Kidney Issues

Joseph Mercola

Semaglutide, the blockbuster drug being used for weight loss, is slated to bring in more than $10 billion in annual sales but serious adverse e!ects are emerging.

A study using data from Eudravigilance, Europe’s system for analyzing adverse reactions to medications, found a high prevalence of gastrointestinal disorders among users.

Other semaglutide patients “experienced rapid worsening of kidney function” after use.

Semaglutide has also been associated with cancer, pancreatitis and retinopathy complications, including hemorrhage and blindness.

Long-term use of GLP-1RAs like semaglutide may even leave your small intestine as inelastic as a loose spring, causing a potentially fatal intestinal obstruction.

Image: Towfiqu barbhuiya @ Unsplash

Latest articles

Dawn Lester & David Parker … As we have shown in many...
Dawn Lester & David Parker Modern medicine is widely acclaimed as being...
Dawn Lester & David Parker In parts one and two, we showed...
Dawn Lester & David Parker In the three previous parts of this...
Roger Koops For those who may not recall Chicken Little (AKA Henny...
Tristan Coleman Does the latest ‘climate consensus’ study show a genuine agreement...

Thank you!

Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.

Thank you.

Thank you!

The form has been submitted successfully!